Pharma BD Deal Intelligence

AbbVie Inc. / Genmab A/S

2020 · Co-Development · $3.9B · Complete

Announcement Sentiment

100

Strongly positive

Outcome Score

Worked — the deal delivered on its rationale.

CORRECTION: The originally requested Pfizer/Genmab $1.9B bispecific deal from 2022 does not exist. The landmark Genmab bispecific deal was AbbVie/Genmab, announced June 2020. AbbVie paid $750 million upfront for a broad oncology collaboration to jointly develop and commercialize three bispecific antibody candidates including epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37, and DuoBody-CD3x5T4. Total potential value up to $3.9 billion with development, regulatory, and sales milestones. Companies share US and Japan profits 50:50; Genmab receives 22-26% tiered royalties on ex-US/Japan sales.

Key facts

Announced Jun 10, 2020
Closed Jun 10, 2020
Deal value $3.9B
Deal type Co-Development
Therapeutic area Oncology
Indications Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Solid Tumors
Key assets epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37, DuoBody-CD3x5T4, DuoBody bispecific platform
Mechanism CD3xCD20 bispecific T-cell engager, CD37-targeting HexaBody, CD3x5T4 bispecific T-cell engager

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals